CompletedPhase 1NCT03316144
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
Studying Lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Principal Investigator
- Junyuan Qi, MD, PhDBlood Diseases Hospital, Chinese Academy of Medical Sciences
- Intervention
- Toripalimab(biological)
- Enrollment
- 13 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2017 – 2019
Study locations (1)
- Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03316144 on ClinicalTrials.govOther trials for Lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07372352Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07198087A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsOno Pharmaceutical Co. Ltd
- RECRUITINGNANCT07191431A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）Ruijin Hospital
- RECRUITINGPHASE1, PHASE2NCT07018752A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasThe Lymphoma Academic Research Organisation
- RECRUITINGNANCT07058064WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)Mayo Clinic
- RECRUITINGPHASE1NCT06699771Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell MalignanciesGC Cell Corporation
- RECRUITINGPHASE2NCT06530550PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNANCT06296368DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology ClinicsUNC Lineberger Comprehensive Cancer Center